Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Business Model:
Revenue: $10M
Employees: 201-500
Address: 55 Cambridge Pkwy Ste 800E
City: Cambridge
State: MA
Zip: 02142
Country: US
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. They accelerate Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning with seemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology. Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies. They attract, develop, and retain the top scientific, entrepreneurial, and managerial talent in the world.
Contact Phone:
+16178681888
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2007 | Ze-gen | Series A | 5.5M |
11/2013 | Moderna Therapeutics | Venture Round | 110M |
2/2007 | Everyday Solutions | Series A | 6.8M |
11/2012 | TransMedics | Venture Round | 36M |
7/2016 | Indigo | Series C | 100M |
9/2018 | Indigo | Series E | 250M |
9/2017 | Indigo | Series D | 203M |
5/2022 | ProFound Therapeutics | Private Equity Round | 75M |
1/2009 | Celexion | Venture Round | - |
3/2022 | Vesalius Therapeutics | Venture Round | 75M |
11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
5/2009 | Visterra | Seed Round | 3.3M |
3/2003 | Hypnion | Series B | 47.5M |
1/2020 | Ohana Biosciences | Venture Round | - |
11/2013 | Editas Medicine | Series A | 43M |
3/2004 | Pervasis Therapeutics | Seed Round | 500k |
1/2020 | Ring Therapeutics | Venture Round | 50M |
11/2021 | Alltrna | Venture Round | 50M |
8/2009 | Advanced Electron Beams | Series C | 0 |
10/2015 | Janssen Global Services | Venture Round | 32M |
1/2003 | VIEO | Series B | 15M |
2/2005 | Seahorse Bioscience | Series C | 11.5M |
3/2009 | Seahorse Bioscience | Series D | 6M |
6/2003 | Ellacoya Networks | Venture Round | 14M |
11/2013 | EcoSense Lighting | Venture Round | 15M |
1/2004 | Genomics Collaborative | Venture Round | - |
9/2005 | Carbon Design Systems | Series C | 5.3M |
5/2015 | Denali Therapeutics | Series A | 217M |
7/2019 | Valo Health | Series A | 100M |
2/2009 | BlackDuck | Series D | 5M |
10/2002 | Tira Wireless | Series A | 3M |
7/2007 | Tira Wireless | Series D | 5M |
3/2020 | Sigilon | Series B | 80.3M |
12/2014 | Seres Therapeutics | Series C | 48M |
2/2016 | Indigo | Series B | 48.5M |
1/2007 | Ensemble Therapeutics | Venture Round | - |
5/2015 | Joule Unlimited, Inc. | Private Equity Round | 40M |
6/2018 | Kaleido | Series C | 101M |
6/2006 | Zingku | Venture Round | 1M |
11/2015 | Evelo Biosciences | Series A | 35M |
10/2007 | BDNA | Series D | 0 |
1/2006 | Interactive Supercomputing | Series A | 4.5M |
3/2017 | Oasys Water | Series B | 4M |
10/2005 | Affinity Express | Venture Round | 3M |
5/2012 | Sesen Bio, Inc. | Series A | 20M |
1/2004 | Carbon Design Systems | Series B | 10M |
6/2012 | YourBio Health | Series A | 10M |
2/2007 | BIND Therapeutics | Series A | 2.5M |
9/2006 | Carbon Design Systems | Series D | 5M |
4/2009 | Avedro | Series B | 10M |
2/2002 | BG Medicine | Venture Round | 11M |
6/2011 | MedidaMetrics | Venture Round | 8.5M |
11/2014 | Indigo | Series A | 7.5M |
9/2003 | Selventa | Series A | 0 |
10/2009 | LS9 | Series C | 25M |
1/2003 | Blue Agave Software | Series A | 7M |
11/2015 | Codiak Biosciences | Series A | 31M |
1/2006 | T2 Biosystems | Series A | 5.5M |
10/2022 | Cellarity | Series C | 121M |
1/2018 | Inzen Therapeutics | Venture Round | - |
5/2010 | T2 Biosystems | Series C | 0 |
11/2016 | YourBio Health | Series C | 10M |
9/2021 | YourBio Health | Venture Round | 21M |
10/2022 | Inari | Series E | 0 |
12/2019 | Cellarity | Funding Round | 50M |
12/2013 | Visterra | Series A | 8.1M |
8/2002 | Flamenco Networks | Series B | 7.4M |
3/2006 | Helicos BioSciences | Series B | 40M |
7/2016 | TransMedics | Private Equity Round | 0 |
3/2017 | CIBO Technologies | Venture Round | 30.3M |
8/2005 | Intio | Series A | 829k |
12/2002 | Integrated Development Enterprise | Venture Round | 13.3M |
7/2008 | Agios | Series A | 33M |
9/2017 | Kaleido BioSciences | Series B | 65M |
4/2007 | TransMedics | Series D | 0 |
11/2006 | Mascoma | Series B | 30M |
9/2018 | KSQ Therapeutics | Series C | 80M |
10/2017 | KSQ Therapeutics | Series B | 76M |
11/2007 | BIND Therapeutics | Series B | 16M |
5/2021 | Inari | Series D | 0 |
5/2021 | Invaio Sciences | Series C | 88.9M |
9/2020 | Generate Biomedicines | Venture Round | 50M |
11/2009 | Receptos | Series A | 25M |
2/2009 | Oasys Water | Series A | 10M |
3/2004 | CombinatoRx | Series C | 30M |
6/2005 | BlackDuck | Series B | 12M |
7/2008 | BG Medicine | Series D | 40M |
3/2015 | Red Rock Biofuels | Venture Round | - |
3/2002 | Affinnova | Series A | 4M |
2/2015 | EcoSense Lighting | Series C | 25M |
7/2021 | Ring Therapeutics | Series B | 117M |
8/2021 | Laronde | Series B | 440M |
5/2005 | Netuitive | Series C | 5M |
1/2021 | Valo Health | Series B | 190M |
7/2006 | Mascoma | Series A | 4M |
8/2020 | Indigo | Series F | 360M |
1/2017 | Incredible Foods | Venture Round | - |
4/2021 | Repertoire Immune Medicines | Series B | 0 |
11/2018 | Axcella | Series E | 0 |
8/2002 | NuVox | Private Equity Round | 78.5M |
12/2015 | Rubius Therapeutics | Series A | 25M |
7/2022 | Apriori Bio | Series A | 0 |
10/2013 | Axcella | Series A | 10.8M |
5/2021 | Laronde | Series A | 50M |
6/2012 | Tangent Medical Technologies | Venture Round | 7.9M |
8/2019 | Inari | Series C | 89M |
7/2003 | Affinnova | Series B | 6M |
6/2009 | Janssen Global Services | Series A | 15M |
5/2008 | Intio | Convertible Note | 1M |
3/2018 | Foghorn Therapeutics | Venture Round | 50M |
9/2003 | IntelliVid | Series A | 5.5M |
6/2010 | Everyday Solutions | Venture Round | 2.8M |
1/2006 | Epitome Biosystems | Venture Round | - |
10/2008 | T2 Biosystems | Series B | 0 |
3/2005 | Tira Wireless | Series B | 2.5M |
5/2016 | TransMedics | Series F | 0 |
12/2003 | Blue Agave Software | Series B | 6M |
1/2004 | EngeneOS | Venture Round | - |
6/2017 | Rubius Therapeutics | Series B | 120M |
12/2011 | Permeon Biologics | Venture Round | 2.5M |
1/2004 | TransMedics | Series B | 27.6M |
3/2018 | Rubius Therapeutics | Series C | 100M |
10/2020 | Senda Biosciences | Series A | 88M |
4/2008 | VisEn Medical | Series B | 0 |
3/2005 | Tira Wireless | Debt Financing | 2.5M |
10/2000 | Hypnion | Series A | 10.4M |
3/2017 | Boragen | Series A | 10M |
5/2004 | Ensemble Discovery | Series A | 15M |
3/2012 | Receptos | Venture Round | 30M |
11/2007 | Ensemble Discovery | Series B | 15M |
11/2021 | Generate Biomedicines | Series B | 0 |
5/2008 | Selecta Biosciences | Seed Round | 2.5M |
5/2008 | Jinko Solar | Series A | - |
8/2008 | Quanterix | Series A | 15M |
10/2011 | BlackDuck | Series E | 12M |
11/2007 | Novomer | Series A | 6.6M |
8/2009 | Novomer | Series B | 14M |
3/2006 | TransMedics | Series C | 0 |
4/2013 | Syros Pharmaceuticals | Series A | 30M |
10/2017 | Visterra | Series C | 0 |
4/2007 | Netuitive | Series D | 8M |
11/2017 | Codiak Biosciences | Series C | 76.5M |
7/2017 | Evelo Biosciences | Series B | 50M |
12/2013 | Axcella | Series B | - |
12/2012 | Moderna Therapeutics | Venture Round | 40M |
3/2007 | LS9 | Series A | 5M |
4/2010 | Selecta Biosciences | Series C | 15M |
5/2014 | Seres Therapeutics | Series B | 10M |
11/2013 | Seres Therapeutics | Series A | 10.5M |
10/2005 | Integrated Development Enterprise | Venture Round | 1.5M |
3/2004 | Zalicus | Series D | 29.5M |
8/2011 | T2 Biosystems | Series D | 0 |
8/2008 | Tetraphase Pharmaceuticals | Series A | 0 |
5/2009 | Carbon Design Systems | Series E | 7.5M |
1/2008 | Carbon Design Systems | Series E | 6M |
10/2021 | CIBO Technologies | Series C | 0 |
9/2009 | Tetraphase Pharmaceuticals | Series B | 0 |
11/2006 | Tetraphase Pharmaceuticals | Series A | 10M |
3/2006 | Tira Wireless | Series C | 13M |
11/2012 | Tangent Medical Technologies | Series B | 8.6M |
1/2002 | Renovis | Series B | 0 |
7/2020 | Omega Therapeutics | Series B | 85M |
1/2006 | Calpurnia Corporation | Series B | 8M |
10/2007 | Interactive Supercomputing | Series B | 11M |
1/2015 | Tarveda Therapeutics | Series B | 21M |
1/2016 | Codiak Biosciences | Series B | 61M |
11/2017 | Repertoire Immune Medicines | Series A | 25M |
5/2011 | YourBio Health | Series A | 4.5M |
3/2010 | Sesen Bio, Inc. | Series A | 35M |
10/2007 | LS9 | Series B | 15M |
6/2005 | Brainshark | Series C | 0 |
4/2010 | Joule Unlimited, Inc. | Series B | 30M |
9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
9/2004 | Ellacoya Networks | Venture Round | 7M |
7/2002 | Continuum Photonics | Series B | 14M |
9/2006 | Intio | Series B | 2M |
1/2002 | CombinatoRx | Series B | 40M |
1/2001 | AnVil Informatics, Inc | Series A | - |
6/2010 | Acceleron Pharma | Venture Round | 10.3M |
1/1999 | Integrated Development Enterprise | Seed Round | - |
12/2005 | Resolvyx Pharmaceuticals | Series A | 17M |
7/2005 | Ellacoya Networks | Series D | 13.5M |
2/2007 | BlackDuck | Series C | 12M |
5/2005 | Codon Devices | Series A | 13M |
7/2004 | BlackDuck | Series A | 5M |
1/2012 | Tarveda Therapeutics | Series A | 2.8M |
6/2003 | Nanostream Inc. | Series C | 22M |
9/2007 | Kovio | Series D | 19.5M |
5/2008 | Mascoma | Series C | 61M |
7/2008 | Accuri Cytometers | Series C | 13M |
6/2011 | Kovio | Venture Round | 0 |
3/2021 | Omega Therapeutics | Series C | 126M |
8/2007 | Adnexus | Series C | 15.5M |
7/2004 | ZoomInfo | Series A | 7M |
12/2013 | Tarveda Therapeutics | Series B | 21M |
11/2012 | Quanterix | Series C | 0 |
1/2021 | Tessera Therapeutics | Series B | 0 |
11/2011 | Agios | Series C | 78M |
10/2006 | Morphotek | Series D | 0 |
9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
8/2022 | Senda Biosciences | Series C | 123M |
6/2006 | Adnexus | Series B | 27M |
2/2012 | Helicos BioSciences | Series A | 27M |
1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
3/2013 | T2 Biosystems | Series E | 40M |
8/2010 | Visterra | Debt Financing | 6M |
10/2014 | Visterra | Series B | 30M |
8/2005 | Pervasis Therapeutics | Series B | 12.4M |
9/2012 | WikiCell Designs | Series A | 10M |
10/2006 | SiCortex | Series B | 21M |
6/2010 | BIND Therapeutics | Series C | 12.4M |
3/2013 | Receptos | Series B | 30M |
8/2006 | Acceleron Pharma | Series B | 30M |
10/2014 | Selecta Biosciences | Private Equity Round | 20M |
12/2005 | Hypnion | Series B | 0 |
8/2014 | YourBio Health | Series B | 16M |
2/2009 | Selecta Biosciences | Series B | 15.1M |
10/2014 | Syros Pharmaceuticals | Series B | 53M |
11/2012 | Visterra | Series A | 26.1M |
6/2016 | Visterra | Series C | 23.1M |
3/2013 | Janssen Global Services | Venture Round | 13.5M |
4/2011 | Janssen Global Services | Series B | 18.4M |
4/2004 | Continuum Photonics | Series C | 17.5M |
3/2003 | Adnexus | Series A | 13M |
8/2009 | Pervasis Therapeutics | Series C | 17.4M |
9/2004 | SiCortex | Series A | 21M |
6/2009 | Polatis | Venture Round | 8M |
2/2004 | Morphotek | Series C | 26M |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
12/2010 | LS9 | Series D | 30M |
8/2015 | Editas Medicine | Series B | 0 |
12/2006 | Codon Devices | Series B | 20M |
10/2007 | Acceleron Pharma | Series C | 31M |
1/2005 | Revivio | Series C | 25M |
10/2010 | Accuri Cytometers | Series E | 6M |
10/2003 | AVEO Oncology | Series B | 42.7M |
2/2017 | Tarveda Therapeutics | Series D | 30M |
3/2010 | TransMedics | Series E | 0 |
8/2009 | Accuri Cytometers | Series D | 4M |
2/2012 | Polatis | Venture Round | 0 |
6/2010 | Tetraphase Pharmaceuticals | Series C | 0 |
1/2019 | Sana Biotechnology | Seed Round | - |
7/2009 | Kovio | Series E | 20M |
9/2014 | BlackDuck | Series F | 0 |
4/2022 | Tessera Therapeutics | Series C | 0 |
6/2020 | Sana Biotechnology | Series A | 700M |
6/2003 | Trusted Network Technologies | Series A | 6M |
8/2004 | Affinnova | Series C | 4.5M |
10/2019 | Cygnal Therapeutics | Venture Round | 65M |
8/2016 | Denali Therapeutics | Series B | 130M |
8/2017 | Omega Therapeutics | Series A | 28.4M |
12/2022 | Montai Health | Series A | 50M |
2/2021 | Cellarity | Series B | 0 |
12/2004 | Pervasis Therapeutics | Series A | 2M |
8/2005 | Extraprise | Venture Round | 0 |
12/2017 | Janssen Global Services | Series B | 25M |
1/2008 | Pervasis Therapeutics | Venture Round | 9.8M |
5/2015 | Axcella | Series C | 39M |
1/2020 | Invaio Sciences | Venture Round | - |
1/2012 | Joule Unlimited, Inc. | Series C | 70M |
3/2013 | Avedro | Series D | 0 |
7/2022 | Apriori Bio | Series A | 0 |
5/2022 | ProFound Therapeutics | Series A | 0 |
4/2022 | Tessera Therapeutics | Series C | 0 |
3/2022 | Vesalius Therapeutics | Series A | 0 |
11/2021 | Generate Biomedicines | Series B | 0 |
11/2021 | Alltrna | Venture Round | 0 |
10/2021 | CIBO Technologies | Series C | 0 |
9/2021 | YourBio Health | Venture Round | 0 |
8/2021 | Laronde | Series B | 0 |
7/2021 | Ring Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|